Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.

safety of first-line treatment of advanced NSCLC with negative PD-L1 expression and EGFR, ALK, and ROS1 wild-type. After being screened to meet the inclusion criteria, they will receive IBI318 combined

lung carcinoma
proto-oncogene tyrosine-protein kinase ros
EGFR
ROS1
  • 0 views
  • 06 May, 2022
  • 1 location
APG-2449 in Patients With Advanced Solid Tumors

APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449 demonstrated potent

lung cancer
esophagus cancer
cancer of the ovary
lung carcinoma
esophageal cancer
  • 38 views
  • 04 Oct, 2022
  • 7 locations
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

This phase III trial studies how well nivolumab and ipilimumab works with or without local consolidation therapy in treating patients with stage IV non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the …

lung cancer
nivolumab
monoclonal antibodies
carcinoma
tumor cells
  • 53 views
  • 19 Jun, 2022
  • 5 locations
A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

The study comprises two phases: phase I dose escalation (including PK run-in period and treatment period) and phase II study.

lung cancer
neutrophil count
serum bilirubin
cancer chemotherapy
crizotinib
  • 0 views
  • 24 Feb, 2022
  • 40 locations
Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy

This is a prospective single arme real-world study clinical study, which aims to investigate the overall benefit and safety of consolidative therapy in advanced NSCLC (stage III/IV) patients , who do not progress after front line systemic therapy (chemotherapy, target therapy or immunological checkpoint inhibitors).

lung cancer
lung carcinoma
granulocyte count
metastasis
liver metastasis
  • 12 views
  • 25 Jan, 2021
  • 1 location
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases (CABRAMET)

This is a multicenter, open-label, exploratory, single-arm, prospective phase II study to assess the efficacy and safety profile of cabozantinib in patients with brain metastases from metastatic renal cell carcinoma (mRCC).

metastasis
cabozantinib
brain metastases
neutrophil count
  • 2 views
  • 21 Feb, 2022
  • 4 locations
A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma (CRU3)

The purpose of this study is to define the objective response rates (ORR) of Lorlatinib in subjects with ALK+ lymphomas resistant or refractory to ALK inhibitors.

  • 0 views
  • 04 May, 2022
  • 1 location
Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients (TOTEM)

This is a Phase I study of repotrectinib in combination with osimertinib in patients with advanced or metastatic EGFR mutant non small cell lung cancer (NSCLC). The study will be conducted in 2 parts, Part Ia and Part Ib, and its purpose will be to find the incidence of dose-limiting …

osimertinib
kidney function test
carcinoma
erlotinib
neutrophil count
  • 0 views
  • 04 Oct, 2022
  • 4 locations
Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo)

The purpose of this study is to find out how effective the combination of crizotinib and fulvestrant is in shrinking lobular breast cancer tumours. The investigators will also be assessing the side effects of the combination of crizotinib tablets and fulvestrant injections. The side effects and the doses of crizotinib …

mammogram
CDH1
HER2
solid tumour
hormone therapy
  • 6 views
  • 09 Feb, 2022
  • 5 locations
LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer

The goal of this project is to characterize the genetic profile of patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) using liquid biopsies

epidermal growth factor
lung carcinoma
HER2
carcinoma
BRAF
  • 21 views
  • 13 Oct, 2021
  • 12 locations